Medicare drug price negotiations need something new

Welch urges GOP to continue Medicare drug price negotiations
Vermont Senator Peter Welch is among lawmakers urging the Trump administration not to roll back efforts that make medications less expensive.
Medicare drug price negotiations need something new: a floor
The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by introducing floors.
Trump Impact on Medicare Drug Price Negotiations Uncertain
Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.
Medicare to Negotiate Prices for 15 More Drugs, Including Ozempic
Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with disabilities, federal health officials announced in a news release. The negotiations,
Medicare targets 15 more drugs for price negotiations — including Ozempic
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
The talks around drugs including Novo Nordisk’s Wegovy, GSK’s Trelegy Ellipta, and Pfizer’s Xtandi will set Medicare prices that go into effect in 2027.
Trump Reverses Some Biden Drug Pricing Initiatives, Potentially Impacting Medicare Costs
Experts suggest that most Americans will not experience immediate changes in their out-of-pocket health care expenses.
Trump rolls back effort to lower Medicare, Medicaid drug costs
Trump’s executive order halts an effort to cap the copayment for generic medications at $2 for Medicare beneficiaries.
Medicare, Medicaid Out-of-Pocket Drug Costs Expected to Increase
The directive for the Department of Health and Human Services to develop and test new models aimed at lowering drug costs through the
Health Affairs22h
Medicare Negotiations Could Fuel, Not Stifle, Innovation
Transparency in the program is more than just a mechanism for fair pricing—it is a driving force that diminishes the returns ...
AARP6d
Millions on Medicare Will Save on Prescription Drugs in 2025
Hays and her husband who have a Medicare Part D drug plan. As a result, she expects to shell out a lot less at the pharmacy ...